MediciNova Shares Fall After NAFLD Drug Fails to Meet Primary Trial Endpoints

Shares of MediciNova Inc. (NASDAQ: MNOV) fell sharply in premarket trading Monday after the biopharmaceutical company reported that its experimental drug, tipelukast (MN-001), failed to meet the primary goals of a Phase 2 clinical trial for nonalcoholic fatty liver disease (NAFLD) and associated conditions.

Trial Misses Primary Goals

MediciNova announced topline results from the MN-001-NATG-202 trial, a randomized, double-blind, placebo-controlled study involving 40 patients. The trial's primary endpoint, a statistically significant reduction in serum triglycerides at Week 24, was not achieved.

While the drug showed a significant reduction at Week 4, this effect was not maintained through the end of the 24-week treatment period. The mean decrease in serum triglycerides for the tipelukast group was 45.8 mg/dL compared to 14.4 mg/dL for the placebo group, a difference that was not statistically significant (p=0.113).

Mixed Secondary Endpoint Data

Despite the primary endpoint failure, the trial data showed statistically significant improvements in other cardiovascular health markers. The company reported positive results for cholesterol levels, which could be a point of focus in future analyses.

Key secondary endpoint results include:

Ad

• HDL Cholesterol (HDL-C): Increased by 3.3 mg/dL in the tipelukast group, while the placebo group saw a decrease of 2.4 mg/dL (p=0.0048).
• HDL Particle Concentration (HDL-P): Increased by 3.62 µmol/L in the treatment group versus a 0.9 µmol/L decrease in the placebo group (p=0.018).

Other measurements, including a reduction in liver fat and body weight, showed a numerical trend toward improvement but did not reach statistical significance.

Market Reaction and Next Steps

Investors reacted to the headline miss, sending MediciNova shares down 14.7% in premarket trading. A failure to meet primary endpoints in a mid-stage trial is a significant setback for a drug's development pathway, often requiring companies to reassess their strategy.

MediciNova noted that tipelukast had a generally favorable safety profile with no serious adverse events related to the drug. The company stated it will conduct further detailed analyses to determine the next steps for clinical development, including the potential patient population and design for future studies.